Date published: 2026-9-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

PAPP-A CRISPR/Cas9 KO Plasmid (m): sc-422113

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • PAPP-A CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PAPP-A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PAPP-A Antibody (B-7): sc-365226
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    PAPP-A CRISPR/Cas9 KO Plasmid (m)

    sc-422113
    20 µg
    $397.00

    Overview

    Mouse Pappa encodes pregnancy-associated plasma protein A (PAPP-A), a secreted metalloproteinase that cleaves insulin-like growth factor binding proteins, most prominently IGFBP4, to increase local IGF bioavailability. By modulating IGF1/IGF2 signaling through IGF1R and downstream PI3K–AKT and MAPK cascades, PAPP-A influences cell proliferation, survival, differentiation, and extracellular matrix remodeling. PAPP-A activity has been linked to processes such as placental and reproductive biology, vascular smooth muscle behavior, and tissue repair, making it relevant to mechanistic studies of growth regulation and inflammation-associated remodeling. Dysregulated IGF axis control involving PAPP-A is frequently examined in models of metabolic dysfunction, cardiovascular pathology, and cancer-associated stromal interactions without implying clinical outcomes.

    PAPP-A CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Pappa gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Pappa together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Pappa open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PAPP-A protein expression.

    This CRISPR knockout system enables efficient generation of Pappa-deficient cell models for investigation of PAPP-A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Pappa exon(s) critical for PAPP-A function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Pappa genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by PAPP-A CRISPR/Cas9 KO Plasmid (m) and PAPP-A CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Pappa locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by PAPP-A HDR Plasmid (m) and PAPP-A HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Pappa homology arms to support homology-directed repair at defined Pappa target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.